Next Phase Newsletter

A venture capital firm based in California that invests in early-stage, technology-driven companies. The firm has recently started exploring life sciences/healthcare investment opportunities and is considering companies in various sectors. The initial check size of the firm can range from $500K – $2M. The firm also runs a program for those who has already participated in accelerator/incubator programs and want to further initial proofs of concept and early market validation to demonstrate long term product/market fit, product roadmap, and business model. Companies that have already launched and want to expand go-to market and reach profitability is welcome to participate in this program as well.

The firm invests in impactful, early-stage technology companies. Within life sciences and healthcare sectors, the firm is interested in medical devices (both 510k and PMA) with a strong data or hardware component, digital health, technologies that leverage AI or big data analytics. The firm will not consider traditional therapeutics or diagnostics companies. In terms of disease area, the firm is opportunistic.

The firm can act as either lead or co-investor and is open to working with all kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a developer of gene therapy treatments founded in 2013 and is a headquartered in the US. The firm is a wholly owned subsidiary of a large pharma. The company has an integrated gene therapy platform for developing medicines in these core areas: ophthalmology, hematology, immunology, and CNS/neurodegenerative disease. Currently, the firm is actively seeking early-stage opportunities that fit their strategic interests for early-stage partnering, in-licensing, and more. The firm seeks opportunities globally.

The firm is interested in innovative therapeutics that can supplement their pipeline in the aforementioned therapeutic/disease areas. The firm’s strongest interests lie in gene therapies, but the firm is also interested in biologics they can utilize in adeno-associated viral (AAV) vectors that have been engineered in-house through the firm’s proprietary platform to enable efficient therapeutic delivery. In terms of stage of development, the firm is interested in evaluating opportunities from the earliest stages, from lead optimization and beyond. The firm is not interested in technologies that fall in other life science sectors, including medical devices, diagnostics, and digital health.

The firm seeks to be a flexible partner with opportunities they engage in, and have no strict requirements for the company or management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm based in the Midwest focused on early-stage health technology investments with a consumer-focus. The firm is looking for companies with solutions that drive consumer engagement and health accountability (these do not have to sell D2C, most of their companies do not). The firm’s newest fund is a $150M fund, through which the firm will focus on investing in early-stage, consumer-centric digital health technologies. The firm’s initial investments generally range from $1,000,000 to $5,000,000. The firm is primarily thesis-focused and invests from Seed to Series B, with a focus just at or before the A round.

The firm is seeking digital health companies focused on the empowering consumers to be better stewards of their health and their healthcare expenditures. Accordingly, the firm is not interested in technology that solve problems solely within payers and providers, such as billing, care coordination for hospitals, or EHR platforms. The firm is indication agnostic, though has interest in chronic illnesses, social determinants, behavioral health, and personalized care among others.

The firm does not have set management team requirements. The firm will play a very active role post-investment, traditionally by taking board seats, providing key sales introductions, assisting with scaling, hiring, and providing network support.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a family office/venture capital firm based in New York. The firm manages an evergreen fund that operates free from the constraints of traditional venture capital funds. The firm seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Private Equity firm that was founded in 2011 with offices in USA. The firm is currently making investments out of its vintage 2020 fund. The firm looks to make primarily growth equity investments ranging from $5-$30 million with most investments falling in the $10-$30 million range. The firm is willing to review opportunities from around the Globe.

The firm is currently interested broadly in the healthcare space including Medical Technology, Therapeutics, Diagnostics, Laboratory Equipment, Healthcare IT and R&D services. For medical technology the firm is looking for companies that have at least an alpha prototype and have some efficacy data.  For companies working with therapeutics the firm is looking for assets that are in Phase II of clinical trials and will only consider companies in Phase I if they have efficacy data. The firm generally does not look for companies in the cardiovascular space and they are open to orphan indications. The firm is also open to investing in companies that have products already on the market.

The firm looks for a strong management team to be in place and is open to invest in both private and publicly held companies. For companies that are privately held the firm generally looks to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Taiwan invests from an evergreen fund, and is a multi-stage investor, with investments made from seed stage all the way to IPO. The firm invests both in Taiwan and internationally, including in the US and Canada.  Investments are typically of $500,000-2 million.

The firm invests in a variety of sectors including medical devices, therapeutics, and digital health/AI.  The firm prefers to invest in companies with a pipeline of multiple assets rather than in single asset companies.  For therapeutics, the firm looks internationally for novel assets: within Taiwan, the firm focuses on repurposed drugs.

The firm prefers to invest in companies that already have a complete team.  For medical device companies, this must include commercial/sales staff.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading healthcare venture capital firm with multiple offices in USA invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. The firm invests in both privately held and publicly traded companies through a variety of investment approaches.

The firm has raised nearly $2 billion in capital commitments and is investing from a fourth core fund of $585 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and Europe but may also consider opportunities in the Middle East.

The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests across a range of stages, from development through profitability, but prefers to back technologies that have attained proof of concept data.

The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.